Retrieval of p53 Protein in Paraffin-Embedded Head and Neck Tumor Tissues

Archives of Otolaryngology--Head and Neck Surgery

Volumn 119, Issue 11, 1993, Pages 1206-1209

  Pavelic, Zlatko P ^a   Portugal, Louis G ^a   Gootee, Michael J ^a   Stambrook, Peter J ^a   Smith, Christopher ^a   Mugge, Richard E ^a   Pavelic, Ljiljana ^a   Wilson, Keith ^a   Buncher, C Ralph ^a   Li, Ya Qin ^a   Mcdonald, John S ^a   Gluckman, Jack L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROTEIN P53; ZINC SULFATE;

ARTICLE; CONTROLLED STUDY; EMBEDDING; GENE MUTATION; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROWAVE RADIATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; TISSUE FIXATION; TISSUE SECTION;

COMPARATIVE STUDY; GENES, P53; HEAD AND NECK NEOPLASMS; HEAT; HUMAN; IMMUNOHISTOCHEMISTRY; NEOPLASMS, SQUAMOUS CELL; PARAFFIN; PROTEIN P53; RETROSPECTIVE STUDIES; STAINING AND LABELING;

EID: 0027375962     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archotol.1993.01880230048008     Document Type: Article

References (49)

1. Gapany M, Pavelic ZP, Kelley DJ, et al. Immunohistochemical detection of c-myc protein in head and neck tumors. Arch Otolaryngol Head Neck Surg. In press.
2. Craven JM, Pavelic ZP, Stambrook PJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 1992;12:2273-2276.
3. Rumsby G, Carter RL, Gusterson BA. Low incidence of ras oncogene activation in human squamous cell carcinomas. Br J Cancer. 1990;61:365-368.
4. Field JK, Lamothe A, Spandidos DA. Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res. 1986;6:595-600.
5. Somers KD, Cartwright SL, Schechter GL. Amplification of the int-2 gene in human head and neck squamous cell carcinomas. Oncogene. 1990;5:915-920.
6. Leonard JH, Kearsley JH, Chenevix-Trench G, et al. Analysis of gene amplification in head and neck squamous cell carcinomas. Int J Cancer. 1991;48:511-515.
7. Spandidos DA, Lamothe A, Field JK. Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res. 1985; 5:221-224.
8. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene. 1989;4:1463-1468.
9. Kawano SH, Okamura K, Hashimoto N. Immunohistochemical localization of c-myc oncogene product and EGF receptor in oral squamous cell carcinoma. J Oral Pathol Med. 1990;19:1-4.
10. Yokota J, Tsuwetsugu-Yokota V, Battifora H, Le Fevre C, Cline MJ. Alterations of myc, myb and rasHa proto-oncogene in cancers are frequent and show clinical correlations. Science. 1986;231:261-267.
11. Berenson JR, Yang J, Mickel R. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. Oncogene. 1989;4:1111-1116.
12. Zhou DJ, Casey G, Line MJ. Amplification of int-2 in breast cancers and squamous carcinomas. Oncogene. 1988;2:279-282.
13. Erisbruch A, Blick M, Lee JS, Sacks PG, Gutterman I. Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumours. Cancer Res. 1987;47:3603-3605.
14. Riviere A, Becker J, Loning T. Comparative investigation of c-erb-B2/neu expression in head and neck tumors and mammary cancer. Cancer. 1991;67:2142-2149.
15. Field JK, Spandidos DA, Malliri A, Yiagnisis M, Gosney JR, Stell PM. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer. 1991;64:573-577.
16. Schipper JJ, Frixen UH, Behrens J, et al. E-cadherin expression in squamous cell carcinomas of head and neck. Cancer Res. 1991;51:6328-6337.
17. Lane, DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev. 1990;4:1-8.
18. Levine AJ. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology. 1990;177:419-426.
19. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 1991;351:453-456.
20. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science. 1991;253:49-53.
21. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature. 1989;342:705-708.
22. Campo E, de la Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res. 1991;51:4436-4442.
23. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 Mutations in nonastrocytic human brain tumors. Cancer Res. 1991;51:6202-6205.
24. Maurakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991;51:5520-5525.
25. Cote RJ, Jhanwar SC, Novick S, Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res. 1991;51:5410-5416.
26. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252:706-709.
27. Okamoto A, Sameshima Y, Yamada Y, et al. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res. 1991;51:5632-5636.
28. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res. 1991;51:5171-5176.
29. Blount PL, Ramel S, Raskind WH, et al. 17p Allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res. 1991;51:5482-5486.
30. Baker SJ, Preisinger AC, Jessup JM, et al. p53 Gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1992;50:7717-7722.
31. Hollstein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A. 1990;87:9958-9961.
32. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217-221.
33. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335:675-679.
34. Rodrigues NR, Rowan A, Smith MEF, et al. p53 Mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87:7555-7559.
35. Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 1991;52:3965-3971.
36. Bartek J, Bartkova J, Vojtesek B, et al. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer. 1990;46:839-844.
37. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 Expression in colorectal tumors. Am J Pathol. 1991;138:807-813.
38. Pavelic ZP, Gluckman JL, Gapany M, et al. Improved immunohistochemical detection of p53 protein in paraffin-embedded tissues reveals elevated levels in most head and neck and lung carcinomas. Anticancer Res. 1992;12:1389-1394.
39. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues. J Histochem Cytochem. 1991;39:741-748.
40. Pavelic K, Pavelic ZP, Denton D, et al. Immunohistochemical detection of c-myconcoprotein in paraffin embedded tissues. J Exp Pathol. 1990:5:143-153.
41. Banks L, Matlashewski G, Crawford LV. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem. 1986;159:529-534.
42. Pavelic ZP, Pavelic K, Carter CP, Pavelic LJ. Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol. 1992;118:16-22.
43. Pavelic K, Pavelic ZP, Preisler HD. c-myc Detection in bone marrow biopsies. Leukemia Res. 1991;15:1075-1078.
44. Pavelic ZP, Sever Z, Fontain RN, et al. Detection of P-glycoprotein with JSB-1 monoclonal antibody in B-5 fixed and paraffin-embedded cell lines and tissues. Selec Cancer Therap. 1991;7:49-58.
45. Cardo-Cordon C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melahmed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38:1277-1287.
46. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. EMBO J. 1990;9:1595-1602.
47. Mulligan LM, Matlashewski GJ, Serable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcoma. Proc Natl Acad Sci U S A. 1990;87:5863-5867.
48. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
49. Munck-Wickland E, Estrom S, Jungmark E, et al. p53 Immunostaining in cis lesions of the larynx. Cancer Detect Prev. 1993;17:89.